SCHEMBL703101

SCHEMBL703101

Cc1cc(C(=O)O)ccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.65
ALDH1A1 P00352 2/20 0.53
MAPT P10636 1/20 0.53
MRGPRX4 Q96LA9 1/20 0.53
SRD5A2 P31213 1/20 0.52
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 2/20 0.52
MYC P01106 1/20 0.52
ESR1 P03372 1/20 0.52
PTPN7 P35236 1/20 0.52
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
TAS1R2 Q8TE23 1/20 0.51
GRM1 Q13255 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MCL1 Q07820 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL28759691 0.98 TSHR (0.63) TSHRALDH1A1MAPTMRGPRX4SRD5A2
SCHEMBL8802168 0.86 ALDH1A1 (0.52) TSHRALDH1A1MAPTMRGPRX4SRD5A2
SCHEMBL4352652 0.84 HTT (0.53) TSHRALDH1A1MAPTSRD5A2TAS1R3
SCHEMBL7845572 0.83 TAS1R3 (0.49) TSHRALDH1A1MAPTMRGPRX4SRD5A2
SCHEMBL697363 0.83 TSHR (0.65) TSHRALDH1A1MAPTMRGPRX4SRD5A2
SCHEMBL2972020 0.83 TAS1R3 (0.51) TSHRALDH1A1MAPTMRGPRX4SRD5A2
SCHEMBL312135 0.83 MAPT (0.52) TSHRALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL29619400 0.83 TSHR (0.65) TSHRALDH1A1MAPTMRGPRX4SRD5A2
SCHEMBL29554593 0.83 MAPT (0.52) TSHRALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL11025910 0.81 TAS1R3 (0.50) TSHRALDH1A1MAPTMRGPRX4SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111972603-A Selenium-rich buckwheat noodles and preparation method thereof 颍上县世菊食品有限公司 2020-11-24 CN claimed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US claimed
CN-119908369-A Mosquito-repellent bracelet containing N, N-diethyl-2-hydroxy-2-phenylacetamide 北京斯瑞朗文生物科技有限公司 2025-05-02 CN disclosed
EP-3976617-B1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2025-04-23 EP disclosed
CN-115093389-B 6-Amide chroman-3-carboxamide derivative, preparation method and application thereof 广州医科大学 2024-10-18 CN disclosed
WO-2024153106-A1 OXADIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国药科大学 2024-07-25 WO disclosed
CN-115974807-B 2-Phenyl-5-biphenyl-1, 3, 4-oxadiazole compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-05-31 CN disclosed
US-20240067600-A1 SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) UNIVERSITY OF KANSAS (US) 2024-02-29 US disclosed
EP-4289838-A2 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2023-12-13 EP disclosed
CN-112441907-B Method for co-producing mono-substituted methylbenzoic acid and mono-substituted phthalic acid 山东友道化学有限公司 2023-10-31 CN disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
US-5420128-A Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-05-30 US disclosed
EP-0612723-A1 Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-08-31 EP disclosed
EP-0611749-A1 Substituted amic acid derivatives useful for treatment of arteriosclerosis BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-08-24 EP disclosed
EP-0604019-A1 N-Acetonylbenzamides and their use as fungicides ROHM AND HAAS COMPANY (US) 1994-06-29 EP disclosed
US-5254584-A Controlling phytopathogens ROHM AND HAAS COMPANY (US) 1993-10-19 US disclosed
EP-0503099-A1 PYRIMIDINE DERIVATIVE, PRODUCTION THEREOF, AND ANDROGEN INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-09-16 EP disclosed
US-4824834-A TREATING GOUT OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1989-04-25 US disclosed
EP-0269859-A2 Pyrazolotriazine compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 EP disclosed
EP-0159291-A1 Ink composition for the ink-jet printing process CIBA-GEIGY AG (CH) 1985-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067600-A1 SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) MTCH2, TIMM50, TIMM10 TSHR 3992/4885ALDH1A1 3811/4885MAPT 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.